mITT-LOCF population | 24Â months | Â | Â | Â | ||
---|---|---|---|---|---|---|
Chondroitin sulfate | Celecoxib | p valuea | Â | Â | Â | |
(n = 69) | (n = 69) |  |  |  | ||
Cartilage volume loss (%) | ||||||
Lateral compartment | –4.1 ± 3.1 | –4.4 ± 3.0 | 0.814 |  |  |  |
 Condyle | –3.0 ± 3.1 | –4.1 ± 3.7 | 0.144 |  |  |  |
 Plateau | –5.8 ± 4.7 | –4.8 ± 3.5 | 0.182 |  |  |  |
Medial compartment | –6.3 ± 3.2 | –8.1 ± 4.2 | 0.018 |  |  |  |
 Condyle | –5.5 ± 3.9 | –7.7 ± 4.7 | 0.008 |  |  |  |
 Plateau | –7.6 ± 4.0 | –8.6 ± 4.8 | 0.276 |  |  |  |
Synovial membrane thicknessb (mm) | 0.13 ± 0.25 | 0.14 ± 0.24 | 0.948 |  |  |  |
Synovial fluid volume (ml) | –2.6 ± 14.5 | –2.0 ± 11.8 | 0.776 |  |  |  |
BML scoreb | 1.1 ± 1.7 | 0.8 ± 1.7 | 0.322 |  |  |  |
ATP population | 12Â months | 24Â months | ||||
Chondroitin sulfate | Celecoxib | p valuea | Chondroitin sulfate | Celecoxib | p valuea | |
(n = 57)c | (n = 63) | (n = 57)c | (n = 63) | |||
Cartilage volume loss (%) | ||||||
 Lateral compartment | –3.4 ± 2.7 | –3.3 ± 2.5 | 0.932 | –4.6 ± 3.0 | –4.4 ± 2.8 | 0.753 |
  Condyle | –2.5 ± 3.2 | –3.0 ± 3.0 | 0.234 | –3.4 ± 3.0 | –4.2 ± 3.6 | 0.316 |
  Plateau | –4.6 ± 3.5 | –3.8 ± 3.1 | 0.194 | –6.3 ± 4.6 | –4.8 ± 3.5 | 0.081 |
 Medial compartment | –4.5 ± 2.6 | –5.6 ± 3.0 | 0.049 | –6.6 ± 3.3 | –8.4 ± 4.2 | 0.021 |
  Condyle | –3.8 ± 3.2 | –5.0 ± 3.8 | 0.100 | –5.7 ± 4.0 | –8.1 ± 4.7 | 0.010 |
  Plateau | –5.5 ± 3.0 | –6.6 ± 3.8 | 0.155 | –8.0 ± 4.2 | –9.0 ± 4.8 | 0.334 |
Synovial membrane thicknessb (mm) | 0.03 ± 0.18 | 0.06 ± 0.18 | 0.579 | 0.15 ± 0.26 | 0.15 ± 0.24 | 0.731 |
Synovial fluid volume (ml) | –5.5 ± 12.6 | –1.8 ± 9.2 | 0.326 | –3.9 ± 15.4 | –2.1 ± 12.2 | 0.945 |
BML scoreb | 0.7 ± 1.4 | 0.3 ± 1.2 | 0.051 | 1.1 ± 1.7 | 0.8 ± 1.7 | 0.322 |